Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain

Human papillomavirus (HPV) is one of the main causes of infection-related cancer. The bivalent vaccine (2vHPV) (16/18) and quadrivalent (6/11/16/18) HPV vaccine (4vHPV) have been included in the Spanish vaccination calendar since 2007. The new nonavalent HPV vaccine (9vHPV), approved in Europe in 20...

Full description

Bibliographic Details
Main Authors: Jesús De La Fuente, Juan José Hernandez Aguado, María San Martín, Paula Ramirez Boix, Sergio Cedillo Gómez, Noelia López
Format: Article
Language:English
Published: Taylor & Francis Group 2019-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cervical cancer
cost-effectiveness
genital warts
hpv
spain
nonavalent hpv vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2018.1560770

Internet

http://dx.doi.org/10.1080/21645515.2018.1560770

Similar Items